[
    [
        {
            "time": "2021-05-12",
            "original_text": "云南白药(000538.SZ)拟战略入股上海医药持股达18.02%",
            "features": {
                "keywords": [
                    "云南白药",
                    "上海医药",
                    "战略入股",
                    "持股18.02%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "云南白药(000538.SZ)拟战略入股上海医药持股达18.02%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05-11",
            "original_text": "上海医药(02607.HK)建议向上海潭东及云南白药发A股筹143.83亿人民币",
            "features": {
                "keywords": [
                    "上海医药",
                    "云南白药",
                    "定增",
                    "募资143.83亿"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)建议向上海潭东及云南白药发A股筹143.83亿人民币",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05-11",
            "original_text": "云南白药：拟参与认购上海医药定增",
            "features": {
                "keywords": [
                    "云南白药",
                    "上海医药",
                    "定增认购"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "云南白药：拟参与认购上海医药定增",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-05-11",
            "original_text": "向前看，入股上海医药对于云南白药的医药商业板块全国性扩张及国际化发展意义是非常重大的。",
            "features": {
                "keywords": [
                    "云南白药",
                    "上海医药",
                    "全国性扩张",
                    "国际化发展"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "向前看，入股上海医药对于云南白药的医药商业板块全国性扩张及国际化发展意义是非常重大的。",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-11",
            "original_text": "上海医药(601607.SH)拟定增募资不超143.84亿元由上海潭东及云南白药认购",
            "features": {
                "keywords": [
                    "上海医药",
                    "云南白药",
                    "定增募资",
                    "143.84亿"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607.SH)拟定增募资不超143.84亿元由上海潭东及云南白药认购",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-05-11",
            "original_text": "上海医药：拟定增募资不超143.84亿元，云南白药认购112亿元",
            "features": {
                "keywords": [
                    "上海医药",
                    "云南白药",
                    "定增募资",
                    "112亿认购"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药：拟定增募资不超143.84亿元，云南白药认购112亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]